Trump Tariff Regime Raises Costs for US Biotech Firms Relying on Imported Pharmaceutical Inputs

US biotech companies are reporting increased costs due to Trump's tariff regime, which has raised prices on imported pharmaceutical inputs and raw materials. The new tariff framework is forcing firms to reassess supply chains, with industry groups warning of downstream effects on drug development timelines and consumer prices.